Home > News > MIV Therapeutics Drug-Eluting Stent Coating
September 24th, 2003
MIV Therapeutics Drug-Eluting Stent Coating
Abstract:
MIV Therapeutics Inc. has received a mid-point milestone interim progress report from the University of British Columbia (UBC) on the development of its proprietary HAp (hydroxyapatite) multi-layer coating with drug-eluting capabilities. "The research work on multi-layer coating applications is progressing on schedule. Our deposition methods have shown promising results with respect to nano-porosity and drug encapsulation for drug-eluting stents."
Source:
MIV Therapeutics
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||